このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Oropharyngeoesophageal Topical Anesthesia Versus Intravenous Propofol -Ketamine Sedation for Upper Gastrointestinal Endoscopy

2026年6月18日 更新者:Zagazig University

Oropharyngeoesophageal Topical Anesthesia Prototype Device Versus Intravenous (Propofol -Ketamine Sedation) for Upper Gastrointestinal Endoscopy

Esophagogastroduodenoscopy (EGD) is an essential and widely used diagnostic and therapeutic procedure in gastroenterology. EGD can be performed in association with topical anesthesia of the pharynx, intravenous anesthesia, or with their combination. Sedation is required to alleviate anxiety, provide analgesia, amnesia and to improve endoscopic performance specifically in therapeutic procedures. However, sedation-related gastrointestinal endoscopy complications when occur, may lead to significant morbidity and occasional mortality especially with moderate and deep sedation. Cardiopulmonary complications resulting from aspiration, oversedation, hypoventilation, vasovagal reflex, and airway obstruction account for more than 50% of all complications associated with upper endoscopy.With regard to the most common sedation regimen used in different countries. In the United States, more than 75% of endoscopists use a benzodiazepine plus narcotic combination, with the combination of midazolam and fentanyl being the most common. A significant percentage of endoscopists (43%) also use propofol regularly, mainly in a hospital setting. In Germany, the most frequently used agents are midazolam (82%) and propofol (74%), and the most common sedation regimens used are propofol plus benzodiazepines (38%) and benzodiazepines plus an opioid (35%). With regard to usage of topical anesthesia during upper gastrointestinal endoscopy, in the United Kingdom it was reported that 63% of endoscopists used topical anesthesia regularly during performance of upper gastrointestinal endoscopy. While twenty percent did not use pharyngeal anesthesia at all, and 17% used pharyngeal anesthesia sometimes. Topical pharyngeal anesthesia currently is a requirement for upper endoscopy to provide patients with the best comfort in unsedated EGD. In Hong Kong, 10% Xylocaine pump spray (AstraZeneca, Sodertalje, Sweden) is the pharyngeal anesthesia generally used as a premedication in unsedated EGD. Many studies have compared topical anesthetic agents to other formulations and techniques such as viscous, lozenge, lollipop, and nebulized lidocaine administration. However, it is still unclear which technique is optimal in terms of its influence on the gag reflex, patient tolerability, and pain. Serious allergic reactions were considered to be a risk of local anesthesia in earlier publications, but these are extremely rare. More attention is being paid to the risk of overdosing because lignocaine, the most widely used substance, is a respiratory depressant and an overdose can result in convulsion, hypotension, bradycardia, and even cardiac arrest. As the spray is rapidly absorbed by mucous membranes, the dose should be limited to 200 mg in adults (20 sprays), and in children the limit is 10 sprays. However British Thoracic Society recommends an upper limit of 8.2 mg/kg. The aim of the study is providing more effective, safer, tolerable and offers quicker recovery technique using either the modified Oropharyngeoesophageal Topical Anesthesia (OPETA) technique or conventional intravenous sedation by prepared mixture of propofol and ketamine (ketofol 4:1) .

調査の概要

詳細な説明

This study is a randomized prospective clinical study that was conducted in department of Anesthesia, Intensive Care & Pain management, Faculty of Medicine, Zagazig University Hospitals on 60 patients scheduled to undergo elective upper GI endoscopy during the period from January 2023 to July 2023. Patients classified into two groups: PK Group: 30 patients received intravenous sedation using prepared mixture of propofol and ketamine (in the ratio 4:1). OPETA Group: 30 patients planned for modified Oropharyngeoesophageal Topical Anesthesia by OPETA prototype tool

Inclusion criteria:

Both sex, patients aged between 21-64 years old undergoing elective upper GI endoscopy after taking informed consent, ASA class II /III, BMI < 30 kg/m2

Exclusion criteria:

Hypersensitivity to drugs included in the study, Difficult airway or known airway problems, Active bleeding from esophageal varices, Emergency procedure, Low base line oxygen saturation < 92% at room air, Cases expected to need general anesthesia for the procedure as judged by endoscopist .

All participants were subjected to:

Obtaining of history and physical examination including vital signs, cardiac and chest condition as well as excluding criteria. Routine laboratory investigations included Complete blood count (CBC), Random blood sugar, coagulation profile (PT, PTT, INR), liver function tests , renal function tests .

General and airway examination was done. All patients were kept fasting for 4 hours from clear fluids and 6 hours from other foods. Midazolam 2-2.5 mg was given to all patients at holding area.

Study design:

After routine pre-operative evaluation, standard monitors were connected to the patients: pulse oximetry, noninvasive blood pressure and electrocardiogram and baseline parameter were recorded (peripheral oxygen saturation, mean arterial pressure and heart rate). Intravenous (IV) line will be inserted and atropine IV 1 mg administered for all patients. Patients will be allocated into two equal groups by a computer-generated randomization table:

Group (PK) (n=30):

Patients received intravenous sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation.The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) (table 1) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.

Group (OPETA) (n=30):

Every patient by him or herself or by help of anesthetist topicalized the anterior tonsillar pillar on both sides and the posterior one third of the tongue as well as the posterior pharyngeal wall using xylocain gel 5 % on the tip of his index or middle finger then after 5-7 minutes the patient inserted his middle finger deeply into his mouth as a test for tolerability before the insertion of OPETA tool (the patient was instructed not to swallow the used local anesthetic but gurgle it as long as possible). While the head tilted forward ("chin on chest"), Lubricated Oropharyngeoseogageal pack (OPETA device), soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by the patient himself or herself with assistance from the anesthetist and patients swallowing into the esophagus. To ensure effective topical anesthesia and patient tolerance, the pack was left in place for three to five minutes before being moved up, down, clockwise and anti-clockwise.. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through the device until the patient is comfortable. For all patients, the maximum local anesthetic dose (5 mg/kg of lidocaine without adrenaline and 7 mg/kg of a lidocaine with adrenaline 1:200000) was meticulously considered. However, we tried to keep the maximum dosage at 5 mg/kg as we dealing with topical anesthesia at the mucous membrane.

The Oropharyngeo-esophygeal Topical Anesthesa (OPETA) device:

It is a handmade device of a patented concept (patency no 23733, academy of scientific research and technology, ARST. Egypt, it is originally used as supraglottic topical anesthesia device (Nofal 2010).

The prototype OPETA device consists of orogastric tube surrounded by a cotton gauze of 5 cm. width. The tube and device size are age dependent and usually of 16-gauge tube size. The tip of the orogastric tube is burnt e.g., by a flame of lighter and simultaneously clamped by a needle holder. Air under pressure is then pushed through the tube port using a 10 ml syringe to verify integrity of the closed tip. Starting from the burnt closed tip, the orogastric tube was punctured with a 21-gauge needle in two perpendicular planes with 1 cm in between each puncture within the same plane for 45 to 50 cm in adult cases representing the length of a line passing from the mouth to earlobe then to xyphoid process. 5 cm wide cotton gauze was wrapped over the punctured part of the tube and secured with 2-0 Mersilk.

After inserting the device into the oropharyngeal cavity and esophagus, local anesthetic (LA) /adrenaline mixture was injected into the punctured tube when required. The injected LA was sprayed through the puncture sites to the surrounding cotton gauze that is in contact with the oropharyngeal and esophageal mucosa, anesthetizing it. During the device insertion, if it is required to make the device less malleable for easier insertion, part of an ureteric guide wire or ureteric catheter cover could be inserted within the tube of the device to strengthen it. After getting the patient sedated or topically anesthetized, endoscopist started the procedure.The modified Aldrete's scoring system was used for the discharge of all patients from recovery. Achievement of at least 9 out of 10 scores was the criteria for discharge in this study. Twenty four hour after the procedure all patients were asked through telephone connection about their experiences regarding the intraprocedural events, they were asked to score their satisfaction level during the procedure in terms of recalling any painful or other undesirable intraprocedural events.

Monitoring:

Standard monitors for all cases include patient's heart rate, oxygen saturation, and MAP pre-procedural (basal) for both topical and sedation groups then every 5 minutes throughout the procedure until the patient is fully alert. Side effects such as hypotension and bradycardia were recorded, if hypotension occurs (decrease in MAP more than 20% from baseline) it was treated with normal saline and if blood pressure was not corrected, ephedrine 5 mg was administered incrementally, and if bradycardia occurs (HR < 60 beats/min) it was treated with atropine 0.01 mg/kg).

Note: all upper GI endoscopy procedures was preformed by OLYMPUS EVIS EXERA III CV- 190 .

Post procedural assessment:

  1. Patient assessment:

    • Two separate questionnaires were asked to the patients in order to rate the procedure 24 hours after discharge when they become completely alert (through telephone connection). The patients answered the following questions:
    • The difficulty in insertion of OPETA device.
    • Discomfort they felt during procedure. Answers was given on a 0 -10-mm numeric rating scale. The left end of the scale (0 mm) will be defined as ''not at all'' and the right end (10 mm) as ''extremely.
  2. Endoscopist assessment:

The endoscopist assessed the following:

  1. Difficulty in introducing the endoscope.
  2. The overall technical difficulty of the examination.
  3. Gagging whether occurred or not. For endoscopist's assessment the 0-10 numeric rating scale was the measurement scale where 0 means the procedure was extremely comfortable and 10 means that it was extremely uncomfortable.

Data collection:

Patient characteristics (Age, Sex, ASA physical status class, BMI). Indications of endoscopic procedure. Baseline heart rate, mean arterial blood pressure (MAP), and oxygen saturation were recorded every five minutes throughout endoscopic procedure and every 10 minutes when the patients at PACU.

Patient Assessment: numeric rating scale (0 …………..…….10)

  1. Discomfort felt during the procedure.
  2. Willing to Re-do in OPETA group. Endoscopist Assessment: numeric rating scale (0 …………….. 10) 1. Difficulty in introducing the endoscope. 2. Gagging with esophageal intubation. 3. The endoscopist satisfaction. Number of doses in PK group.

Time:

  1. OPETA time: Time from administration of self or helped oral topical anesthesia till getting the OPETA device manipulation tolerated by the patient (moving the OPETA tool up and down clockwise and anti-clockwise without distressing the patient).
  2. Sedation time: Time from starting intravenous sedation until ability to insert endoscope freely.
  3. Endoscopy time: Time from starting of insertion till removal of the endoscope.
  4. Recovery time: Time since the endoscopist finish the endoscopy until the patient is completely alert and oriented to space and time.
  5. Discharge time: Time from admission to the recovery area to get the patient ready for discharge from the recovery area using modified aldert score.
  6. Total time: summation of previous times. Any complications e.g., systemic toxicity, respiratory depression, desaturation, nausea and vomiting in both studied groups were recorded and managed.

Statistical analysis All data were collected, tabulated and statistically analyzed using SPSS 26.0 for windows (SPSS Inc., Chicago, IL, USA). Quantitative data were expressed as the mean ± SD & median (interquartile range), and qualitative data were expressed as absolute frequencies (number) & relative frequencies (percentage). Independent samples Student's t-test was used to compare between two groups of normally distributed variables while Mann Whitney U test was used for non- normally distributed variables. Percent of categorical variables were compared using Chi-square test or Fisher's exact test when appropriate. All tests were two sided. P value < 0.05 was considered statistically significant (S), P-value ≥ 0.05 was considered statistically insignificant (NS).

研究の種類

介入

入学 (実際)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Sharqia Province
      • Zagazig、Sharqia Province、エジプト、44111
        • Zagazig University Hospitals

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Both sexes.
  • Patients aged between 21-64 years old undergoing elective upper GI endoscopy after taking informed consent.
  • ASA class II /III
  • BMI < 30kg/m2

Exclusion Criteria:

  • Hypersensitivity to drugs included in the study.
  • Difficult airway or known airway problems.
  • Active bleeding from esophageal varices.
  • Emergency procedure
  • Low base line oxygen saturation < 92% at room air.
  • Cases expected to need general anesthesia for the procedure as judged by endoscopist.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:グループ (PK)
患者は、プロポフォールとケタミンの調製混合物(比率 4:1)を使用して静脈内鎮静を受けました。
Included 30 patients received intravenous sedation using prepared mixture of propofol and ketamine (in the ratio 4:1).It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
アクティブコンパレータ:グループ(OPETA)
患者はOPETAプロトタイプツールによる改良型中咽頭食道局所麻酔を受けた
Topicalization was done for the anterior tonsillar pillar on both sides and the posterior 1/3 of tongue and posterior pharyngeal wall using xylocain gel 5 % on tip of his index or middle finger then after 5-7 min, patient inserted his middle finger deeply into his mouth as a test for tolerability before insertion of OPETA tool. While the head tilted forward, Lubricated OPETA device, soaked with 10 ml lidocaine 2 % mixed with adrenaline 1/200000 was gradually placed by the patient with assistance from the anesthetist and patients swallowing into the esophagus. To ensure effective topical anesthesia and patient tolerance, pack was left in place for 3-5 min before being moved up, down, clockwise and anti-clockwise. If necessary, increments of 5 ml of 2% lidocaine/adrenaline mixture was injected through the device until the patient is comfortable. The maximum local anesthetic dose was kept at 5 mg/kg.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Patient discomfort felt during endoscopy
時間枠:24 hour after the procedure
0 -10 numeric rating scale was the measurement scale where 0 means the procedure was extremely comfortable and 10 means that it was extremely uncomfortable.
24 hour after the procedure

二次結果の測定

結果測定
メジャーの説明
時間枠
Mean arterial pressure (MAP)
時間枠:0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
measure the mean arterial pressure in both groups
0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
Heart rate
時間枠:0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
measure heart rate in both groups
0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
Oxygen saturation
時間枠:0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
record oxygen saturation in both groups
0 min ,5 min, 10 min, 15 min, 20 min, 25min, 30 min throughout endoscopic procedure and 0 min, 10 min, 20 min, 30 min when the patients at PACU.
The endoscopist satisfaction
時間枠:immediately after the procedure
For endoscopist's satisfaction assessment the 0-10 numeric rating scale was the measurement scale where 0 means the procedure was extremely comfortable and 10 means that it was extremely uncomfortable.
immediately after the procedure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Mona Shahin, MD、Zagazig University
  • スタディチェア:Osama Nofal, MD、Zagazig University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月1日

一次修了 (実際)

2023年5月30日

研究の完了 (実際)

2023年6月1日

試験登録日

最初に提出

2026年4月21日

QC基準を満たした最初の提出物

2026年4月28日

最初の投稿 (実際)

2026年5月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月23日

QC基準を満たした最後の更新が送信されました

2026年6月18日

最終確認日

2024年12月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する